SCHEMBL6079167

SCHEMBL6079167

O=Cc1ccccc1-c1cnccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
ALOX5AP P20292 2/20 0.40
FEN1 P39748 2/20 0.40
ADRA1D P25100 1/20 0.40
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
METAP2 P50579 1/20 0.38
CYP2A6 P11509 1/20 0.38
GRM5 P41594 2/20 0.38
XDH P47989 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B2 P19099 1/20 0.36
PIM2 Q9P1W9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5414951 0.82 ADRA1A (0.40) ADRA1AADRA1BALOX5APFEN1ADRA1D
SCHEMBL29823771 0.79 KDM4E (0.50) MEN1LMNATHRBBLMKMT2A
SCHEMBL30062580 0.79 KDM4E (0.50) MEN1LMNATHRBBLMKMT2A
SCHEMBL893835 0.79 KDM4E (0.50) MEN1LMNATHRBBLMKMT2A
SCHEMBL10049307 0.79 ALOX5AP (0.41) KMT2AADRA1AADRA1BALOX5APFEN1
SCHEMBL12853973 0.78 ALOX5AP (0.50) MEN1LMNABLMKMT2AADRA1A
SCHEMBL12853984 0.78 ALOX5AP (0.50) MEN1LMNABLMKMT2AADRA1A
SCHEMBL28957625 0.78 CYP11B1 (0.49) MEN1KMT2AADRA1AADRA1BALOX5AP
Hydrochloric Acid SCHEMBL19893873 0.78 KDM4E (0.48) MEN1LMNATHRBBLMKMT2A
SCHEMBL30567475 0.77 TRIM24 (0.46) MEN1LMNATHRBBLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016106106-A2 FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-30 WO disclosed
CN-102471314-A Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction ROTTAPHARM SPA 2012-05-23 CN disclosed
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 MEN1 494/4885LMNA 1769/4885THRB 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.